the estimated efficacy was lowest in children two to 10 years old ( less than or equal to 0 per cent ) and in persons with preexisting diseases that are thought to predispose to pneumococcal disease ( less than or equal to 0 per cent ) , and highest in the group over 10 years old ( 60 per cent ) .
C0008059
children
C0027361
persons